Leptin and plasminogen activator inhibitor-1 levels in children on chronic dialysis

References

• Parekh RS, Gidding SS. Cardiovascular complications in pediatric end stage renal disease. Ped Nephrol. 2005;20:125–131
   Google Scholar
• Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27:848–854
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Dunstan DW, Owen N, Zimmet PZ, Barr EL, Taksin AM. Health and mortality consequences of abdominal obesity: evidence from the AusDiab study. Med J Aust. 2009;191:202–208
   Google Scholar
• Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma leptin levels of a rapid inhibitor of tissue plasminogen activator in young survivor of myocardial infarction. N Eng J Med. 1985;19:1557–1563
   Google Scholar
• Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77–82
   PubMed Web of Science ®Google Scholar
• Marvi A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterscler Thromb Vasc Biol. 1989;19:1582–1587
   Google Scholar
• Mitrio V, Pergola G, Vettor R, et al. Plasma plasminogen activator inhibitor-1 is associated with plasma leptin irrespective of body mass index, body fat mass, and insulin and metabolic parameters in premenopausal women. Metabolism. 1989;48:960–964
   Google Scholar
• Heimburger O, Lönnqvist F, Danielson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. JASN. 1997;8:1423–1430
   Google Scholar
• Daschner M, Tönshoff B, Blum WF, et al. Inappropriate elevation of serum leptin levels in children with chronic renal failure. JASN. 1998;9:1074–1079
   Google Scholar
• Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997;51:1980–1985
   PubMed Web of Science ®Google Scholar
• Howard JK, Lord GM, Clutterbuck EJ, Ghatei MA, Pusey CD, Bloom SR. Plasma immunoreactive leptin concentration in end-stage renal disease. Clin Sci(Lond). 1997;93:119–126
   Google Scholar
• Tsujimoto Y, Shoji T, Tabata T, et al. Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1999;34:832–838
   PubMed Web of Science ®Google Scholar
• Kagan A, Haran N, Leschinsky L, Shuali N, Rapaport J. Leptin in CAPD patients: serum concentration and peritoneal loss. Nephrol Dial Transplant. 1999;14:400–405
   Google Scholar
• Landt M, Parvin A, Dagogo S, Bryant B, Coyne DW. Leptin elimination in hyperleptinemic peritoneal dialysis patients. Nephrol Dial Transplant. 1999;14:731–737
   Google Scholar
• Arkouche W, Juillard L, Delawari E, et al. Peritoneal clearance of leptin in continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1999; 34:839–844
   Google Scholar
• Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest. 1996;98:1277–1282
   PubMed Web of Science ®Google Scholar
• Widjaja A, Keilstein JT, Horn R, Mühlen A, Klein V, Brabant D. Free serum leptin but not bound leptin concentrations are elevated in patients with end stage renal disease. Nephrol Dial Transplant. 2000;15:846–850
   Google Scholar
• Malyszko J, Wolczynski S, Malyszko J, Mysliwiec M. Leptin correlates with hemostatic parameters in CAPD patients. Nephron. 2002;92:721–724
   Google Scholar
• Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism. 1997;46:36–40
   Google Scholar
• Gris JC, Branger B, Vecina F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int. 1994;46:807–813
   PubMed Web of Science ®Google Scholar
• Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab. 1997;82:654–657
   PubMed Web of Science ®Google Scholar
• Segarra A, Chagon P, Martinez-Eyarre C, et al. Circulating levels of plasminogen activator inhibitor-1, tissue plasminogen activator and thrombomodulin hemodialysis patients: biochemical correlations and role as independent predictors of coronary stenosis. J Am Soc Nephrol. 2001;12:1255–1263
   PubMedGoogle Scholar
• Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strangaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol. 1995;5:1581–1584
   Google Scholar
• Ishii Y, Yano S, Maezawa A, Tsuchida A, Wakamatsu R, Naruse T. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron. 1996;73:407–412
   Google Scholar
• Aunsholt NA, Alhbom G, Steffensen G, Glud T. Fibrinolytic capacity in hemodialysis patients treated with recombinant erythropoietin. Nephron. 1992;62:284–288
   Google Scholar
• Opatrny KJ, Vit L, Opatrna S, et al. The effect of erythropoietin on fibrinolysis in hemodialyzed patients. Cas Lek Cesk. 1995;134:136–138
   Google Scholar
• Barawski J, Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis. Clin Appl Thromb Hemost. 2003;9:349–352
   Google Scholar